.jpg "Maria-Alexandra Papadimitriou, BSc photo")
Phd candidate
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
Maria-Alexandra Papadimitriou, Biologist B.Sc., PhD Candidate, Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodristrian University of Athens, Athens, Greece.
My name is Maria-Alexandra Papadimitriou, I studied Biology and received my B.Sc from the Faculty of Biology of the National and Kapodistrian University of Athens (NKUA), and currently I am a 3rd year PhD candidate in the Dept. of Biochemistry and Molecular Biology of the Faculty of Biology of NKUA, under the supervision of Professor Andreas Scorilas. My current research is directed to modern molecular diagnostics towards personalized and precision medicine in bladder cancer and multiple myeloma, focusing on: a. cell-free DNA (cfDNA)/circulating-tumor DNA (ctDNA), and b. tumor-related non-coding RNAs (miRNAs, lncRNAs, tRFs).
Our recent published articles include:
a. miR-25 and miR-181a evaluation in multiple myeloma prognosis:
“Papadimitriou MA et al. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. J Transl Med. 2023, 10.1186/s12967-023-04034-5;
Papadimitriou MA et al. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. Br J Cancer. 2022, 10.1038/s41416-021-01602-8.”
b. the importance of ncRNAs in the orchestration of cancer quiescence: “Soureas K et al. Cancer quiescence: non-coding RNAs in the spotlight. Trends Mol Med. 2023, 10.1016/j.molmed.2023.07.003.”
c. cfDNA levels utility in bladder cancer progression: “Papadimitriou MA et al. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome. Clin Chem. 2023, 10.1093/clinchem/hvac218.”